

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

NCT05813418

Status	RECRUITING
Phase	Not Applicable
Sponsor	Centre Hospitalier Universitaire, Amiens
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (4)

- patient with cancer, whatever initial tumoral histology and disease stage under ICPI treatment (anti-PD1 and/or anti-CTLA-4)
- age \geq 18
- followed in oncology, pneumology, dermatology, gastroenterology departments of Amiens-Picardie University Hospital or Saint Quentin hospital
- who received verbal and written information, and signed the consent form for the study

Exclusion (3)

- non ICPI treated patients
- patient who received a first line of ICPI treatment
- patient who received or is receiving MEK inhibitors as a treatment (because of possible lower response to ICPI treatment when associated)

Locations (1 total)

CHU Amiens Picardie, Amiens, Picardie, France